...
首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates.
【24h】

In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates.

机译:两性霉素B,伊曲康唑,伏立康唑,泊沙康唑,卡泊芬净和特比萘芬对Scytalidium dimidiatum和Scytalidium hyalinum临床分离株的体外活性。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: The objective of this work was to evaluate the in vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafine against clinical isolates of Scytalidium dimidiatum and Scytalidium hyalinum. METHODS: Microdilution testing was performed in accordance with the CLSI M38-A method on 17 S. dimidiatum and 15 S. hyalinum clinical isolates. RESULTS: The MIC ranges of voriconazole, posaconazole, itraconazole, terbinafine, caspofungin and amphotericin B were <0.03 to 0.5 mg/L, 0.06-2 mg/L, <0.03 to >16 mg/L, 0.06-2 mg/L, 0.06-8 mg/L and 0.06-1 mg/L, respectively. CONCLUSIONS: Amphotericin B and voriconazole exhibit the lowest MICs for Scytalidium spp. Voriconazole could be a promising agent for the treatment of these refractory infections.
机译:目的:本研究的目的是评估两性霉素B,伊曲康唑,伏立康唑,泊沙康唑,卡泊芬净和特比萘芬对Scytalidium dimidiatum和Scytalidium hyalinum临床分离株的体外活性。方法:按照CLSI M38-A方法对17株S.idiidiatum和15株S. hyalinum临床分离株进行微量稀释测试。结果:伏立康唑,泊沙康唑,伊曲康唑,特比萘芬,卡泊芬净和两性霉素B的MIC范围分别为<0.03至0.5 mg / L,0.06-2 mg / L,<0.03至> 16 mg / L,0.06-2 mg / L, 0.06-8 mg / L和0.06-1 mg / L。结论:两性霉素B和伏立康唑对Scytalidium spp的MIC最低。伏立康唑可能是治疗这些难治性感染的有前途的药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号